Alkermes plc's decision – against the advice of the FDA – to use an abbreviated, six-item version of the 10-item Montgomery-Asberg Depression Rating Scale (MADRS) in Study 207, one of the main trials with ALKS-5461 (buprenorphine/samidorphan), became a bone of contention in briefing documents made public ahead of Thursday's adcom meeting.